1. Home
  2. MGTX

as of 12-04-2025 3:43pm EST

$8.57
+$0.45
+5.48%
Stocks Health Care Biotechnology: Biological Products (No Diagnostic Substances) Nasdaq

MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.

Chart Type:
Time Range:
Founded: 2015 Country:
United States
United States
Employees: N/A City: NEW YORK
Market Cap: 744.9M IPO Year: N/A
Target Price: $23.83 AVG Volume (30 days): 706.5K
Analyst Decision: Strong Buy Number of Analysts: 6
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -2.11 EPS Growth: N/A
52 Week Low/High: $4.55 - $9.73 Next Earning Date: 11-13-2025
Revenue: $27,417,000 Revenue Growth: 96.83%
Revenue Growth (this year): -20.01% Revenue Growth (next year): 619.95%

AI-Powered MGTX Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated a day ago

AI Recommendation

hold
Model Accuracy: 68.71%
68.71%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Stock Insider Trading Activity of MeiraGTx Holdings plc (MGTX)

Sell
MGTX Oct 21, 2025

Avg Cost/Share

$8.87

Shares

24,000

Total Value

$212,880.00

Owned After

829,494

SEC Form 4

Forbes Alexandria

PRESIDENT & CEO

Sell
MGTX Oct 7, 2025

Avg Cost/Share

$8.39

Shares

47,500

Total Value

$398,525.00

Owned After

1,313,983

SEC Form 4

Share on Social Networks: